Davos Life Science (DavosLife) has announced preliminary results of a phase I clinical trial of its delta-tocotrienol (Naturale3) in patients with resectable pancreatic cancer. Tocotrienols are highly potent members of the Vitamin E family that have been found by researchers to inhibit the growth and survival of various types of cancer cells.
